$ILMN

Meister Keith A. sold $14.4M of ILMN (indirect holdings)

Meister Keith A. sold 87,653 indirectly-held shares of ILLUMINA, INC. (ILMN) at $164.34 ($14.40M total) on 2026-06-01.

Original reporting
SEC EDGAR · Meister Keith A.
Published Jun 1, 2026, 10:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ILMN
Neutral
medium confidence
Mentioned
$ILMN
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNNeutralLow
01

Why it matters

The disclosure may slightly pressure sentiment around ILMN but is unlikely to change valuation absent accompanying operational news.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is not a standalone fundamental catalyst.

03

What to watch

Form 4s often aggregate routine transactions; without additional context (tax, diversification, prior plans), the signal may be overstated versus fundamentals.

Relevance 6/10Novelty 6/10Timing: Filed today (2026-06-01) for an open-market sale at $164.34/share

Background

SEC Form 4 reports insider transactions by directors/officers/10%+ holders; this one is an open-market sale by a director.

Company-level read

Ticker impact

$ILMNNeutralMedium confidence
Context

Illumina director Keith A. Meister sold 87,653 shares in an open-market transaction worth about $14.4M, disclosed via SEC Form 4.

Expected impact

Likely limited/short-lived impact; any move would be sentiment-driven rather than fundamentals.

Evidence & confidence

The filing is an ownership-change disclosure (not earnings/guidance/M&A). It does not indicate a company event, and the sale is not stated as part of a 10b5-1 plan, which can increase attention but still lacks a direct causal catalyst.

Market effects

Minor sentiment read-through for biotech/life-science tools; no direct sector catalyst from this single Form 4.

None specific; US-listed issuer disclosure only.

None specific; transaction is company-internal ownership activity.

Counterpoint

A director sale can reflect diversification or liquidity needs; absence of a stated 10b5-1 plan does not prove bearish intent.

Key entities

  • Illumina, Inc.

    US-listed life-science tools company whose director sold shares via SEC Form 4.

  • Keith A. Meister

    Director who executed the open-market sale disclosed in the filing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNMed

Does Illumina’s (ILMN) New Credit Line Quietly Redefine Its Risk Buffer and Strategic Flexibility?

Illumina (ILMN) secured a new $1.00 billion revolving credit facility, replacing its 2023 agreement. The facility offers variable-rate borrowing and covenant limits, with no amounts drawn initially. This enhances liquidity and financial flexibility amid stronger revenue and earnings guidance. The company's focus remains on clinical sequencing, with risks including competition, China exposure, and research funding. Analysts' revenue growth expectations vary, with some projecting 5.2% annual growt

$ILMNMedAI 8/10

Illumina Stock Is Up 82% in Six Months. The Street’s Target Still Trails It.

Illumina (ILMN) stock has risen 82% in six months, closing at $223.22 on August 24. The surge follows three quarters of raised guidance due to strong clinical sequencing demand. Analysts' average price target is $199, 11% below the current price. TIKR's model values the stock at $259 by late 2030, implying a 16% total return. Potential S&P 500 inclusion adds speculative momentum.

$ILMNHighAI 8/10

Illumina (ILMN) Replaces Prior Deal With $1 Billion Revolving Credit Facility

Illumina (ILMN) has secured a new $1 billion unsecured revolving credit facility, replacing its prior agreement. The facility offers updated covenants and increased flexibility for future financing. According to the company, it will serve as a liquidity backstop and support capital structure decisions. The credit line is expected to fund working capital, equipment, and potential projects, but may impact debt-to-equity metrics if not matched by earnings growth.

$MRNAMedAI 8/10

Three Cancer Research Stocks to Watch After Moderna’s Breakthrough

Moderna's [MRNA] personalized mRNA cancer vaccine, intismeran, met Phase 3 trial endpoints, boosting its shares and Merck's [MRK] as it's administered with Keytruda. Illumina [ILMN] and Pacific Biosciences [PACB] also rose due to their sequencing technology's role. BioNTech [BNTX] gained as investors reassessed mRNA cancer therapies. Moderna reported Q2 revenue of $145M and a net loss of $782M, while Illumina reported Q2 revenue of $1.16B and raised 2026 guidance. BioNTech reported Q2 revenue of